A Phase 3 interventional study of BFF MDI 320/9.6 μg and BFF MDI 160/9.6 μg in Chronic Obstructive Pulmonary Disorder, sponsored by Pearl Therapeutics, Inc.. Completed at 260 sites in 8 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-09-24.
Sponsored by Pearl Therapeutics, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 3 under way, 1 of them phase 3. Budesonide · Pulmonary Disease, Chronic Obstructive.
Among the 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive, this one is the 3rd largest by enrollment, is one of 4 that started in 2016, is one of 15 in phase 3, and was the 28th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →3 of the 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Germany, United Kingdom
Ages 40–80
Maria Joyera Rodríguez · Sites in Germany, Netherlands, Spain and 1 more country
Ages 40+
AstraZeneca · Sites in United States, Argentina, Australia and 34 more countries
Ages 40–80
By country, each count listing its studies:
Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 4 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,389 is above the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 99 across the 43 interventional studies. Of the 37 that completed or were terminated, 16 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 43 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pearl Therapeutics, Inc., one of the names counted as AstraZeneca. Under that name alone:
Pearl Therapeutics, Inc. is the lead sponsor of 42 studies on the registry; none are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 15 (94%) have results posted.
284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca: 14 open now, 15 under way, 4 of them phase 3. Of 264 finished, 127 (48%) have results posted.
Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 5th largest by enrollment of the 194 interventional ones that give a count, is one of 20 that started in 2016, is one of 76 in phase 3, and was the 184th registered.
AstraZeneca’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 1999.
1 of the studies testing budesonide in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07073950AstraZenecaA Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 284 in Pulmonary Disease, Chronic Obstructive:
This tab as a report to print or save as PDF → With an account.
This is a Phase III randomized, double-blind, parallel group, multi-center, 24-week lung function study with BFF MDI (320/9.6 μg and 160/9.6 μg) compared to FF MDI 9.6 μg, BD MDI 320 μg, and open-label Symbicort® TBH (200/6 μg) administered BID.
This is a Phase III randomized, double-blind, parallel group, multi-center, 24-week lung function study with BFF MDI (320/9.6 μg and 160/9.6 μg) compared to FF MDI 9.6 μg, BD MDI 320 μg, and open-label Symbicort® TBH (200/6 μg) administered BID. Subjects will undergo a 1- to 4-week Screening Period. Subjects who successfully complete the Screening Period will be to one of the following five treatment groups:BFF MDI 320/9.6 μg BID (N=660), BFF MDI 160/9.6 μg BID, FF MDI 9.6 μg BID, BD MDI 320 μg BID, Symbicort®, TBH 400/12 μg BID. Following randomization, subjects will enter the Treatment Period and undergo additional treatment visits over 24 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Budesonide and Formoterol Fumarate Inhalation Aerosol 160/4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
Drug: BFF MDI 320/9.6 μg
Budesonide and Formoterol Fumarate Inhalation Aerosol-80/4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
Drug: BFF MDI 160/9.6 μg
Formoterol Fumarate Inhalation Aerosol-4.8 μg per actuation MDI/ 120 inhalations Taken as 2 inhalations BID
Drug: FF MDI 9.6 μg
Budesonide inhalation Aerosol 160 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
Drug: BD MDI 320 μg
Symbicort Turbuhaler 400/12 μg Taken as 2 inhalations BID
Drug: Symbicort® TBH 400/12 μg BID
Drug pages: Budesonide · Formoterol
Blinded Treatment
Also known as: Budesonide and Formoterol Fumarate Inhalation Aerosol
Blinded Treatment
Also known as: Budesonide and Formoterol Fumarate Inhalation Aerosol
Blinded Treatment
Also known as: Formoterol Fumarate Inhalation Aerosol
Blinded Treatment
Also known as: Budesonide Inhalation Aerosol
Drug page: Budesonide/Formoterol Fumarate Dihydrate Inhalation Aerosol
Open Label
Also known as: Symbicort® Turbuhaler
Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24 (BFF MDI Versus FF MDI)
Change from baseline in morning pre-dose trough FEV1 (Forced expiratory volume in 1 second) at Week 24 (BFF MDI versus FF MDI)
Time frame: at Week 24
Change From Baseline in FEV1 AUC0-4 (BFF MDI vs BD MDI)
Changes from baseline in FEV1 AUC0-4 were normalized by taking the area under the curve value and dividing by the length of time under consideration (usually 4 hours). This normalization represents a weighted average of the change from baseline in FEV1 over the 4-hour period.
Time frame: at Week 24
Time to First Moderate or Severe COPD Exacerbation (BFF MDI vs FF MDI).
Time to first moderate or severe COPD (Chronic Obstructive Pulmonary Disease) exacerbation (BFF MDI vs FF MDI).
Time frame: over 24 Weeks (timepoints of 4, 12 & 20 weeks)
Percentage of Subjects Achieving an MCID (Minimal Clinically Important Difference) of 4 Units or More in SGRQ at Week 24
The SGRQ (St. George's Respiratory Questionnaire) is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of BFF MDI, FF MDI, BD MDI, \& Symbicort TBH on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life.
Time frame: at Week 24
Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24 (BFF MDI vs BD MDI)
Change from baseline in morning pre-dose trough FEV1(Forced Expiratory Volume in 1 second) at Week 24 (BFF MDI vs BD MDI)
Time frame: at Week 24
Peak Change From Baseline in FEV1 at Week 24 (BFF MDI vs BD MDI)
Peak change from baseline in FEV1 (Forced Expiratory Volume in 1 second) at Week 24 (BFF MDI vs BD MDI)
Time frame: at Week 24
Change From Baseline in Average Daily Rescue Ventolin HFA Use Over 24 Weeks (BFF MDI vs BD MDI)
Change from baseline in average daily rescue Ventolin HFA use over 24 weeks (BFF MDI vs BD MDI)
Time frame: over 24 Weeks
FEV1 on Day 1, 5 Minutes, Time to Onset of Action Determination
Time to onset of action Day 1 was evaluated by calculating change from baseline in FEV1 at each post-dose timepoint (5min, 15min, 30min, 1hr, 2hr, and 4hr), then comparing each treatment to BD MDI 320 ug. The first timepoint a statistically significant difference from BD MDI 320 ug of ≥100mL was determined to be time of onset for that treatment.
Time frame: Day 1 - 5 Minutes
FEV1 on Day 1, 15 Minutes, Time to Onset of Action Determination
Time to onset of action Day 1 was evaluated by calculating change from baseline in FEV1 at each post-dose timepoint (5min, 15min, 30min, 1hr, 2hr, and 4hr), then comparing each treatment to BD MDI 320 ug. The first timepoint a statistically significant difference from BD MDI 320 ug of ≥100mL was determined to be time of onset for that treatment.
Time frame: Day 1 - 15 Minutes
FEV1 on Day 1, 30 Minutes, Time to Onset of Action Determination
Time to onset of action Day 1 was evaluated by calculating change from baseline in FEV1 at each post-dose timepoint (5min, 15min, 30min, 1hr, 2hr, and 4hr), then comparing each treatment to BD MDI 320 ug. The first timepoint a statistically significant difference from BD MDI 320 ug of ≥100mL was determined to be time of onset for that treatment.
Time frame: Day 1 - 30 Minutes
FEV1 on Day 1, 1 Hour, Time to Onset of Action Determination
Time to onset of action Day 1 was evaluated by calculating change from baseline in FEV1 at each post-dose timepoint (5min, 15min, 30min, 1hr, 2hr, and 4hr), then comparing each treatment to BD MDI 320 ug. The first timepoint a statistically significant difference from BD MDI 320 ug of ≥100mL was determined to be time of onset for that treatment.
Time frame: Day 1 - 1 Hour
FEV1 on Day 1, 2 Hours, Time to Onset of Action Determination
Time to onset of action Day 1 was evaluated by calculating change from baseline in FEV1 at each post-dose timepoint (5min, 15min, 30min, 1hr, 2hr, and 4hr), then comparing each treatment to BD MDI 320 ug. The first timepoint a statistically significant difference from BD MDI 320 ug of ≥100mL was determined to be time of onset for that treatment.
Time frame: Day 1 - 2 Hours
FEV1 on Day 1, 4 Hours, Time to Onset of Action Determination
Time to onset of action Day 1 was evaluated by calculating change from baseline in FEV1 at each post-dose timepoint (5min, 15min, 30min, 1hr, 2hr, and 4hr), then comparing each treatment to BD MDI 320 ug. The first timepoint a statistically significant difference from BD MDI 320 ug of ≥100mL was determined to be time of onset for that treatment.
Time frame: Day 1 - 4 Hours
Substudy: 12-hour PFT Endpoint FEV1 AUC0-12
Substudy: 12-hour PFT (Pulmonary Function Test) endpoint FEV1 (Forced Expiratory Volume) AUC0-12 (Area under the Curve 0-12). Changes from baseline in FEV1 AUC0-12 were normalized by taking the area under the curve value and dividing by the length of time under consideration. This normalization represents a weighted average of the change from baseline in FEV1 over the 12-hour period.
Time frame: at Week 12
This study randomized subjects at 244 study centers in 7 countries, from June 2016 and November 2017. The study period was scheduled to take up to approximately 30 weeks for each individual subject from the time of screening through the follow-up period.
| Milestone | BFF MDI 320/9.6 μg | BFF MDI 160/9.6 μg | FF MDI 9.6 μg | BD MDI 320 μg | Symbicort TBH 400/12 μg |
|---|---|---|---|---|---|
| Started | 655 | 637 | 644 | 206 | 219 |
| Completed | 576 | 567 | 554 | 169 | 190 |
| Not completed | 79 | 70 | 90 | 37 | 29 |
| Withdrew: Adverse event | 27 | 22 | 17 | 13 | 12 |
| Withdrew: Withdrawal by subject | 21 | 20 | 24 | 13 | 10 |
| Withdrew: Lack of efficacy | 16 | 15 | 32 | 8 | 2 |
| Withdrew: Lost to follow-up | 6 | 3 | 5 | 2 | 2 |
| Withdrew: Physician decision | 3 | 2 | 3 | 1 | 2 |
| Withdrew: Protocol disc criteria | 3 | 3 | 4 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 4 | 4 | 0 | 1 |
| Withdrew: Administrative reasons | 3 | 1 | 1 | 0 | 0 |
Change from baseline in morning pre-dose trough FEV1 (Forced expiratory volume in 1 second) at Week 24 (BFF MDI versus FF MDI)
| Liter | BFF MDI 320/9.6 μg | BFF MDI 160/9.6 μg | FF MDI 9.6 μg |
|---|---|---|---|
| Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24 (BFF MDI Versus FF MDI) | 0.036 (0.019 to 0.053) | 0.017 (0.000 to 0.034) | -0.003 (-0.020 to 0.015) |
Changes from baseline in FEV1 AUC0-4 were normalized by taking the area under the curve value and dividing by the length of time under consideration (usually 4 hours). This normalization represents a weighted average of the change from baseline in FEV1 over the 4-hour period.
| Liter | BFF MDI 320/9.6 μg | BFF MDI 160/9.6 μg | FF MDI 9.6 ug | BD MDI 320 ug | Symbicort TBH 400/12 ug |
|---|---|---|---|---|---|
| Change From Baseline in FEV1 AUC0-4 (BFF MDI vs BD MDI) | 0.194 (0.177 to 0.212) | 0.179 (0.161 to 0.197) | 0.161 (0.143 to 0.179) | 0.022 (-0.011 to 0.054) | 0.187 (0.157 to 0.218) |
Time to first moderate or severe COPD (Chronic Obstructive Pulmonary Disease) exacerbation (BFF MDI vs FF MDI).
| Percentage of Participants | BFF MDI 320/9.6 μg | BFF MDI 160/9.6 μg | FF MDI 9.6 μg | BD MDI 320 μg | Symbicort TBH 400/12 ug |
|---|---|---|---|---|---|
| Percentage of Subjects to Exacerbate at 4 Weeks | 3.2 (2.1 to 4.9) | 3.3 (2.2 to 5.1) | 5.5 (4.0 to 7.6) | 7.0 (4.2 to 11.5) | 1.8 (0.7 to 4.8) |
| Percentage of Subjects to Exacerbate at 12 Weeks | 9.8 (7.7 to 12.4) | 9.9 (7.8 to 12.5) | 15.0 (12.4 to 18.1) | 14.9 (10.6 to 20.7) | 8.6 (5.5 to 13.3) |
| Percentage of Subjects to Exacerbate at 20 Weeks | 14.4 (11.9 to 17.4) | 18.5 (15.6 to 21.8) | 20.5 (17.5 to 23.9) | 17.7 (13.0 to 23.9) | 13.1 (9.2 to 18.6) |
The SGRQ (St. George's Respiratory Questionnaire) is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of BFF MDI, FF MDI, BD MDI, \& Symbicort TBH on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life.
| Percentage of Subjects | BFF MDI 320/9.6 μg | BFF MDI 160/9.6 μg | FF MDI 9.6 μg | BD MDI 320 μg | Symbicort TBH 400/12 μg |
|---|---|---|---|---|---|
| Percentage of Subjects Achieving an MCID (Minimal Clinically Important Difference) of 4 Units or More in SGRQ at Week 24 | 48.12 | 47.22 | 41.59 | 43.62 | 53.78 |
Change from baseline in morning pre-dose trough FEV1(Forced Expiratory Volume in 1 second) at Week 24 (BFF MDI vs BD MDI)
| Liter | BFF MDI 320/9.6 μg | BFF MDI 160/9.6 μg | FF MDI 9.6 μg | BD MDI 320 μg | Symbicort TBH 400/12 μg |
|---|---|---|---|---|---|
| Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24 (BFF MDI vs BD MDI) | 0.036 (0.019 to 0.053) | 0.017 (0.000 to 0.034) | -0.003 (-0.020 to 0.015) | -0.028 (-0.060 to 0.003) | 0.039 (0.009 to 0.069) |
Peak change from baseline in FEV1 (Forced Expiratory Volume in 1 second) at Week 24 (BFF MDI vs BD MDI)
| Liter | BFF MDI 320/9.6 μg | BFF MDI 160/9.6 μg | FF MDI 9.6 μg | BD MDI 320 μg | Symbicort TBH 400/12 μg |
|---|---|---|---|---|---|
| Peak Change From Baseline in FEV1 at Week 24 (BFF MDI vs BD MDI) | 0.272 (0.254 to 0.291) | 0.258 (0.239 to 0.276) | 0.243 (0.224 to 0.261) | 0.116 (0.082 to 0.150) | 0.267 (0.253 to 0.299) |
Change from baseline in average daily rescue Ventolin HFA use over 24 weeks (BFF MDI vs BD MDI)
| Puffs per day | BFF MDI 320/9.6 μg | BFF MDI 160/9.6 μg | FF MDI 9.6 μg | BD MDI 320 μg | Symbicort TBH 400/12 μg |
|---|---|---|---|---|---|
| Change From Baseline in Average Daily Rescue Ventolin HFA Use Over 24 Weeks (BFF MDI vs BD MDI) | -1.3 (-1.5 to -1.1) | -1.3 (-1.4 to -1.1) | -1.1 (-1.2 to -0.9) | -0.6 (-0.9 to -0.3) | -1.2 (-1.5 to -0.9) |
Time to onset of action Day 1 was evaluated by calculating change from baseline in FEV1 at each post-dose timepoint (5min, 15min, 30min, 1hr, 2hr, and 4hr), then comparing each treatment to BD MDI 320 ug. The first timepoint a statistically significant difference from BD MDI 320 ug of ≥100mL was determined to be time of onset for that treatment.
| Liter | BFF MDI 320/9.6 μg | BFF MDI 160/9.6 μg | FF MDI 9.6 μg | BD MDI 320 μg | Symbicort TBH 400/12 μg |
|---|---|---|---|---|---|
| FEV1 on Day 1, 5 Minutes, Time to Onset of Action Determination | 0.157 (0.148 to 0.166) | 0.151 (0.142 to 0.161) | 0.160 (0.150 to 0.169) | 0.025 (0.009 to 0.041) | 0.131 (0.115 to 0.148) |
Time to onset of action Day 1 was evaluated by calculating change from baseline in FEV1 at each post-dose timepoint (5min, 15min, 30min, 1hr, 2hr, and 4hr), then comparing each treatment to BD MDI 320 ug. The first timepoint a statistically significant difference from BD MDI 320 ug of ≥100mL was determined to be time of onset for that treatment.
| Liter | BFF MDI 320/9.6 μg | BFF MDI 160/9.6 μg | FF MDI 9.6 μg | BD MDI 320 μg | Symbicort TBH 400/12 μg |
|---|---|---|---|---|---|
| FEV1 on Day 1, 15 Minutes, Time to Onset of Action Determination | 0.190 (0.180 to 0.200) | 0.186 (0.176 to 0.196) | 0.201 (0.191 to 0.211) | 0.040 (0.022 to 0.058) | 0.167 (0.149 to 0.184) |
Time to onset of action Day 1 was evaluated by calculating change from baseline in FEV1 at each post-dose timepoint (5min, 15min, 30min, 1hr, 2hr, and 4hr), then comparing each treatment to BD MDI 320 ug. The first timepoint a statistically significant difference from BD MDI 320 ug of ≥100mL was determined to be time of onset for that treatment.
| Liter | BFF MDI 320/9.6 μg | BFF MDI 160/9.6 μg | FF MDI 9.6 μg | BD MDI 320 μg | Symbicort TBH 400/12 μg |
|---|---|---|---|---|---|
| FEV1 on Day 1, 30 Minutes, Time to Onset of Action Determination | 0.207 (0.196 to 0.217) | 0.207 (0.196 to 0.218) | 0.215 (0.205 to 0.226) | 0.047 (0.028 to 0.066) | 0.190 (0.172 to 0.209) |
Time to onset of action Day 1 was evaluated by calculating change from baseline in FEV1 at each post-dose timepoint (5min, 15min, 30min, 1hr, 2hr, and 4hr), then comparing each treatment to BD MDI 320 ug. The first timepoint a statistically significant difference from BD MDI 320 ug of ≥100mL was determined to be time of onset for that treatment.
| Liter | BFF MDI 320/9.6 μg | BFF MDI 160/9.6 μg | FF MDI 9.6 μg | BD MDI 320 μg | Symbicort TBH 400/12 μg |
|---|---|---|---|---|---|
| FEV1 on Day 1, 1 Hour, Time to Onset of Action Determination | 0.225 (0.213 to 0.236) | 0.221 (0.210 to 0.233) | 0.236 (0.225 to 0.248) | 0.053 (0.033 to 0.073) | 0.211 (0.191 to 0.231) |
Time to onset of action Day 1 was evaluated by calculating change from baseline in FEV1 at each post-dose timepoint (5min, 15min, 30min, 1hr, 2hr, and 4hr), then comparing each treatment to BD MDI 320 ug. The first timepoint a statistically significant difference from BD MDI 320 ug of ≥100mL was determined to be time of onset for that treatment.
| Liter | BFF MDI 320/9.6 μg | BFF MDI 160/9.6 μg | FF MDI 9.6 μg | BD MDI 320 μg | Symbicort TBH 400/12 μg |
|---|---|---|---|---|---|
| FEV1 on Day 1, 2 Hours, Time to Onset of Action Determination | 0.253 (0.241 to 0.265) | 0.234 (0.222 to 0.247) | 0.244 (0.231 to 0.256) | 0.063 (0.042 to 0.085) | 0.221 (0.200 to 0.243) |
Time to onset of action Day 1 was evaluated by calculating change from baseline in FEV1 at each post-dose timepoint (5min, 15min, 30min, 1hr, 2hr, and 4hr), then comparing each treatment to BD MDI 320 ug. The first timepoint a statistically significant difference from BD MDI 320 ug of ≥100mL was determined to be time of onset for that treatment.
| Liter | BFF MDI 320/9.6 μg | BFF MDI 160/9.6 μg | FF MDI 9.6 μg | BD MDI 320 μg | Symbicort TBH 400/12 μg |
|---|---|---|---|---|---|
| FEV1 on Day 1, 4 Hours, Time to Onset of Action Determination | 0.230 (0.216 to 0.243) | 0.215 (0.202 to 0.229) | 0.212 (0.199 to 0.226) | 0.073 (0.049 to 0.097) | 0.209 (0.186 to 0.232) |
Substudy: 12-hour PFT (Pulmonary Function Test) endpoint FEV1 (Forced Expiratory Volume) AUC0-12 (Area under the Curve 0-12). Changes from baseline in FEV1 AUC0-12 were normalized by taking the area under the curve value and dividing by the length of time under consideration. This normalization represents a weighted average of the change from baseline in FEV1 over the 12-hour period.
| Liter | BFF MDI 320/9.6 μg | BFF MDI 160/9.6 μg | FF MDI 9.6 μg | BD MDI 320 μg |
|---|---|---|---|---|
| Substudy: 12-hour PFT Endpoint FEV1 AUC0-12 | 0.135 (0.107 to 0.163) | 0.124 (0.097 to 0.152) | 0.117 (0.089 to 0.145) | 0.024 (-0.028 to 0.075) |
Collected over Adverse events were collected from the time the subject signed informed consent throughout the treatment period and up to 14 days following the last dose of study drug. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BFF MDI 320/9.6 μg | 3/655 (0.5%) | 42/655 (6.4%) | 240/655 (36.6%) |
| BFF MDI 160/9.6 μg | 2/637 (0.3%) | 45/637 (7.1%) | 201/637 (31.6%) |
| FF MDI 9.6 μg | 2/644 (0.3%) | 72/644 (11.2%) | 219/644 (34%) |
| BD MDI 320 μg | 0/206 (0%) | 15/206 (7.3%) | 75/206 (36.4%) |
| Symbicort TBH 400/12 μg | 2/219 (0.9%) | 20/219 (9.1%) | 57/219 (26%) |
| Event | BFF MDI 320/9.6 μg | BFF MDI 160/9.6 μg | FF MDI 9.6 μg | BD MDI 320 μg | Symbicort TBH 400/12 μg |
|---|---|---|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 15/655 | 10/637 | 29/644 | 2/206 | 6/219 |
| PneumoniaInfections and infestations | 4/655 | 5/637 | 6/644 | 0/206 | 3/219 |
| Cardiac failure congestiveCardiac disorders | 1/655 | 1/637 | 1/644 | 2/206 | 1/219 |
| Pancreatitis acuteGastrointestinal disorders | 0/655 | 0/637 | 0/644 | 0/206 | 2/219 |
| Atrial fibrillationCardiac disorders | 1/655 | 5/637 | 2/644 | 1/206 | 0/219 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 2/655 | 2/637 | 4/644 | 0/206 | 1/219 |
| Atrial flutterCardiac disorders | 1/655 | 0/637 | 1/644 | 1/206 | 0/219 |
| Myocardial ischaemiaCardiac disorders | 0/655 | 0/637 | 1/644 | 1/206 | 0/219 |
| Atrioventricular block completeCardiac disorders | 0/655 | 1/637 | 0/644 | 1/206 | 0/219 |
| Coronary artery stenosisCardiac disorders | 0/655 | 0/637 | 0/644 | 1/206 | 0/219 |
| Event | BFF MDI 320/9.6 μg | BFF MDI 160/9.6 μg | FF MDI 9.6 μg | BD MDI 320 μg | Symbicort TBH 400/12 μg |
|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 40/655 | 40/637 | 43/644 | 17/206 | 14/219 |
| Chronic obstructive pulmonary diseaseInfections and infestations | 16/655 | 10/637 | 30/644 | 2/206 | 6/219 |
| Upper respiratory tract infectionInfections and infestations | 25/655 | 21/637 | 20/644 | 5/206 | 3/219 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 14/655 | 6/637 | 6/644 | 0/206 | 8/219 |
| HypertensionVascular disorders | 14/655 | 22/637 | 15/644 | 5/206 | 4/219 |
| CoughRespiratory, thoracic and mediastinal disorders | 7/655 | 15/637 | 15/644 | 7/206 | 0/219 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 12/655 | 11/637 | 9/644 | 7/206 | 3/219 |
| HeadacheNervous system disorders | 19/655 | 8/637 | 15/644 | 3/206 | 1/219 |
| Back painMusculoskeletal and connective tissue disorders | 18/655 | 13/637 | 18/644 | 3/206 | 2/219 |
| Oral candidiasisInfections and infestations | 17/655 | 14/637 | 5/644 | 3/206 | 3/219 |
The Modified Intent-To-Treat (mITT) Population is a subset of the ITT Population, and is defined as all subjects with post-randomization data obtained prior to discontinuation from treatment. The Intent-To-Treat (ITT) Population is defined as all subjects who were randomized to treatment and received any amount of the study treatment.
| Age, Continuous(Years) | BFF MDI 320/9.6 μg | BFF MDI 160/9.6 μg | FF MDI 9.6 μg | BD MDI 320 μg | Symbicort TBH 400/12 μg | Total |
|---|---|---|---|---|---|---|
| Mean | 64.2 ± 7.7 | 64.3 ± 7.6 | 64.1 ± 8.0 | 64.2 ± 7.4 | 65.3 ± 7.0 | 64.3 ± 7.7 |
| Sex: Female, Male(Participants) | BFF MDI 320/9.6 μg | BFF MDI 160/9.6 μg | FF MDI 9.6 μg | BD MDI 320 μg | Symbicort TBH 400/12 μg | Total |
|---|---|---|---|---|---|---|
| Values listed are mITT population — Female | 253 | 260 | 261 | 81 | 78 | 933 |
| Values listed are mITT population — Male | 402 | 377 | 383 | 125 | 141 | 1428 |
| Ethnicity (NIH/OMB)(Participants) | BFF MDI 320/9.6 μg | BFF MDI 160/9.6 μg | FF MDI 9.6 μg | BD MDI 320 μg | Symbicort TBH 400/12 μg | Total |
|---|---|---|---|---|---|---|
| Values listed are mITT population — Hispanic or Latino | 16 | 18 | 21 | 8 | 6 | 69 |
| Values listed are mITT population — Not Hispanic or Latino | 637 | 616 | 623 | 198 | 212 | 2286 |
| Values listed are mITT population — Unknown or Not Reported | 2 | 3 | 0 | 0 | 1 | 6 |
| Race (NIH/OMB)(Participants) | BFF MDI 320/9.6 μg | BFF MDI 160/9.6 μg | FF MDI 9.6 μg | BD MDI 320 μg | Symbicort TBH 400/12 μg | Total |
|---|---|---|---|---|---|---|
| Values listed are mITT population — American Indian or Alaska Native | 2 | 2 | 2 | 0 | 0 | 6 |
| Values listed are mITT population — Asian | 1 | 1 | 0 | 0 | 1 | 3 |
| Values listed are mITT population — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Values listed are mITT population — Black or African American | 19 | 15 | 20 | 9 | 8 | 71 |
| Values listed are mITT population — White | 633 | 619 | 622 | 197 | 210 | 2281 |
| Values listed are mITT population — More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Values listed are mITT population — Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
Showing the first 100 of 260 sites across 8 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2016 to primary completion in Dec 2017, 18 months.
Results were first posted in Sep 2019, 1 year 9 months after primary completion.
Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 18 months is close to that.
Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Budesonide · Formoterol
Pulmonary Disease, Chronic Obstructive →